GENE ONLINE|News &
Opinion
Blog

2021-01-22| COVID-19

COVID-19: LumiraDx’s Antigen Test Gets Approved in Two More Countries

by Eduardo Longoria
Share To

LumiraDx, the next-generation point-of-care diagnostic testing company has announced new approvals in Brazil and Japan for its SARS-CoV-2 Antigen Test. This test is a microfluidic immunofluorescence assay designed to detect SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens. The antigen test yields high sensitivity results12 minutes after the sample’s application.

 

How Does the Platform Work?

The LumiraDx platform is comprised of a small instrument; a microfluidic test strip and secure cloud-based connectivity that provides fast and accurate diagnostic test results to patients in community care settings.

The LumiraDx antigen test works by making use of an incredibly small fluid sample from a nasopharyngeal swab and antibodies with an attached luminescent label to identify the presence of SARS-CoV-2 antigens.

When the antigens from an infected individual come into contact with the labeled antibodies on the microfluidics device (test strip) the two will bind and induce a tiny luminescence that can be identified by the reader included with the test. This test not only benefits from being small and portable but also having storage and operating temperatures that don’t require specialized equipment.

2-30 °C (36-86 °F) storage temperature

15-30 °C (59-86 °F) operating temperature

Image courtesy: LumiraDx

In Which Countries are the Test Approved?

LumiraDx SARS-CoV-2 Antigen Test is commercially available in 30 countries including the US, Europe, Middle East, Africa, and the Asia Pacific. Notably, it received the FDA’s Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein.

Following several studies and audits by the regulatory authorities, LumiraDx has now bagged two new approvals, one from the Brazilian Health Regulatory Agency, or ANVISA (Agência Nacional de Vigilância Sanitária), and another from Japan’s PMDA (pharmaceutical and medical devices agency). The test will be initially supplied to hospitals to help curb the rapid COVID-19 spread.

LumiraDx works with point-of-care diagnostics and has been particularly active during this pandemic. The LumiraDx platform capitalizes on the increased value of point-of-care tests created by the COVID-19 pandemic.

The company, founded in 2014, has further benefited from this past year by successfully raising an estimated $164 million from an undisclosed funding round. This most recent and largest of its three rounds will likely be helpful for LumiraDx to push its products into new markets.

Related Article: COVID-19: Another Study Suggests Pfizer/BioNTech Vaccine is Capable of Neutralizing UK Variant

References
  1. https://www.lumiradx.com/us-en/news-events/lumiradx-receives-sars-cov-2-ag-test-authorization-in-japan-and-brazil
  2. https://www.lumiradx.com/us-en/news-events/lumiradx-receives-fda-uae-for-poc-covid-19-ag-test

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
LATEST
Targeting Metabolism for Noninvasive Multi-Cancer Early Detection Tests
2022-12-08
Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology
2022-12-08
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!